VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern

New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta
– Data also demonstrate trivalent VBI-2901 induced robust and consistent levels of immunity against the ancestral COVID-19 strain and a panel of variants including Beta, Delta, Kappa, and Lambda
– First subject dosed in Phase 1b portion of ongoing study to assess VBI-2905 as (i) a 1-dose booster in individuals previously immunized with an mRNA vaccine, and (ii) a primary 2-dose series in unvaccinated individuals
– Initial VBI-2905 data expected early Q1 2022, subject to speed of enrollment
– Conference call to be held on Wednesday, September 29 at 8:30am ET to discuss preclinical data, Phase 1b study design, and VBI’s COVID-19 and betacoronavirus development strategy

Excerpt from the Press Release:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of the ongoing clinical study of VBI’s SARS-CoV-2 vaccine candidates in approximately 80 adults age 18-54.

VBI’s coronavirus pipeline, which includes multiple vaccine candidates developed using the Company’s proprietary enveloped virus-like particle (eVLP) technology platform, is being developed with the objective to increase the breadth of protection against known and emerging variants of COVID-19. The lead vaccine candidates include:

• VBI-2902: eVLP candidate expressing the prefusion ancestral SARS-CoV-2 spike protein – as previously announced in June 2021, demonstrated robust immunogenicity and a clean safety profile in the Phase 1a portion of the clinical study
• VBI-2905: eVLP candidate expressing a modified prefusion spike protein of the SARS-CoV-2 Beta variant of concern – in current, ongoing Phase 1b clinical study
• VBI-2901: Trivalent eVLP candidate, expressing the prefusion spike protein of ancestral SARS-CoV-2, in addition to the spike proteins from SARS-CoV, and MERS-CoV – first clinical study is expected to initiate H1 2022

Click the button below to read the entire Press Release:

Continue Reading The Press Release